EPO-TRAUMA Trial

ErythroPOietin alfa to prevent mortality and reduce severe disability in critically ill TRAUMA patients: a multi-centre, stratified, double-blind, randomised, placebo-controlled trial. (The EPO-TRAUMA trial)

ErythroPOietin alfa to prevent mortality and reduce severe disability in critically ill TRAUMA patients

Sites30
Patients614

Committee
Contacts
Progress

Study Progress

Country	Recruited
Australia	335
New Zealand	129
Switzerland	45
Saudi Arabia	42
Finland	37
Ireland	21
Slovenia	5
Total	614